Ron Squarer served as Board Chair of Deciphera Pharmaceuticals Inc. (the makers of Qinlock® and vimseltinib) through its acquisition by Ono Pharmaceuticals for ~$2.5 billion (a 75% premium) in June 2024 and was the former CEO of Array Biopharma through its acquisition by Pfizer Inc. for $11.8 billion in August 2019 following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, Array’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is also recognized for inventing Vitrakvi®, Koselugo®, Tukysa®, Retevmo®, Krazati™, and ipatasertib/AKT, among other molecules. Mr. Squarer is currently the Board Chair of ADC Therapeutics (the makers of Zynlonta®) and is a Board member at Travere Therapeutics Inc. (the makers of Filspari®). Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc. (now Pfizer Inc.), a global pharmaceutical and medical device company. As Chief Commercial Officer, he delivered $4 billion in worldwide annual revenue. He joined Hospira from Mayne Pharma, where he served as SVP, Global Corporate and Business Development, when Mayne was acquired by Hospira for over $2 billion. Before Mayne Pharma, he held leadership roles at Pfizer, Inc. (including in Oncology) and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.